Search results for: 'sign cross partnering 2026 2016'

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2026) report offers in-depth insights and exclusive access to preclinical-stage partnering agreements signed by the world’s leading biopharma companies, providing a detailed analysis of deal structures, financial terms and strategic collaborations.

The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2026) report offers in-depth insights and exclusive access to discovery-stage partnering agreements signed by the world’s leading biopharma companies, providing a detailed analysis of deal structures, financial terms and strategic collaborations.

Academic and Non-Profit Partnering Terms and Agreements 2021-2026 provides a detailed understanding and analysis of how and why companies enter Academic and Non-Profit partnering deals. 

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report offers in-depth insights and exclusive access to clinical-stage partnering agreements signed by the world’s leading biopharma companies, providing a detailed analysis of deal structures, financial terms and strategic collaborations.

Global Generic Pharmaceutical Partnering Terms and Agreements 2010 to 2026 report provides a detailed understanding and analysis of how and why companies enter generic pharmaceutical partnering deals. 

Specialty Pharmaceutical Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter specialty pharmaceutical partnering deals. 

Global Biotech Partnering Terms and Agreements 2018 to 2023 report provides a detailed understanding and analysis of how and why companies enter biotech partnering deals.

The Leading Partnering Intelligence Platform for Pharma, Biotech and Diagnostic Dealmakers

Provides comprehensive understanding and unprecedented access to the animal health agreements entered into by the world's leading biopharma companies.

Provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals